journal
MENU ▼
Read by QxMD icon Read
search

ClinicoEconomics and Outcomes Research: CEOR

journal
https://www.readbyqxmd.com/read/30410374/sacroiliac-joint-fusion-health-care-cost-comparison-prior-to-and-following-surgery-an-administrative-claims-analysis
#1
Erin K Buysman, Rachel Halpern, David W Polly
Purpose: To assess real-world expenditures on surgical and non-surgical treatment for sacroiliac joint (SIJ) pain by comparing direct health care costs before and after surgery in patients who underwent an SIJ fusion (SIJF) procedure. Materials and methods: This retrospective observational study examined administrative claims data (January 1, 2010 to February 28, 2017) for adult commercial health plan members with a medical claim for SIJF. Identified patients were included if they had continuous enrollment in the health plan for 12 months pre-SIJF (baseline period) and 12 months post-SIJF (follow-up period)...
2018: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/30410373/real-world-analysis-of-cost-health-care-resource-utilization-and-supportive-care-in-hodgkin-lymphoma-patients-with-frontline-failure
#2
Machaon Bonafede, Joseph Feliciano, Qian Cai, Virginia Noxon, Nicole Princic, Akshara Richhariya, David J Straus
Purpose: The purpose of this study was to evaluate the economic burden of frontline failure (FLF) among classical Hodgkin lymphoma (HL) patients during and after treatment. Patients and methods: The population consisted of adult HL patients identified from January 2010 through September 2015 without any other primary cancer prior to HL diagnosis, who also had a frontline (FL) regimen indicative of curative intent. Patients were characterized as FLF (those who restart, switch to any chemotherapy; had a hematopoietic stem cell transplant; or newly initiated radiation therapy [RT] after discontinuing FL) or non-FLF (those not considered as FLF)...
2018: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/30349338/a-single-blind-multicenter-randomized-controlled-trial-to-evaluate-the-effectiveness-and-cost-of-a-novel-nutraceutical-lopiglik-%C3%A2-lowering-cardiovascular-disease-risk
#3
Andrea Manfrin, Valentina Trimarco, Maria Virginia Manzi, Francesco Rozza, Raffaele Izzo
Context: Cardiovascular disease (CVD) costs the economy €210 billion per year in Europe. There is an association between low-density lipoprotein cholesterol (LDL-C) and CVD risk. Objective: To evaluate the cost and effectiveness of LopiGLIK® (LOPI) in lowering LDL-C and CVD risk. Design: Single blind multicenter randomized controlled trial; patients were divided into two groups, subjected to centralized randomization. Setting: Four Italian regions...
2018: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/30323637/the-role-of-a-best-practice-alert-in-the-electronic-medical-record-in-reducing-repetitive-lab-tests
#4
Harini Bejjanki, Lazarus K Mramba, Stacy G Beal, Nila Radhakrishnan, Rohit Bishnoi, Chintan Shah, Nikhil Agrawal, Neil Harris, Robert Leverence, Kenneth Rand
Background: The recommendations of the American Board of Internal Medicine Foundation's "Choosing Wisely® " initiative recognize the importance of improving the appropriateness of testing behavior and reducing the number of duplicate laboratory tests. Objective: To assess the effectiveness of an electronic medical record Best Practice Alert (BPA or "pop up") intervention aimed at reducing duplicate laboratory tests and hospital costs. Design: Comparison of the number of duplicated laboratory tests performed on inpatients before and after the intervention...
2018: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/30323636/comparison-of-real-world-clinical-and-economic-outcomes-between-the-thermocool-%C3%A2-sf-and-thermocool-%C3%A2-catheters-in-patients-undergoing-radiofrequency-catheter-ablation-for-atrial-fibrillation
#5
Larry Chinitz, Laura J Goldstein, Andrea Barnow, Sonia Maccioni, Mehmet Daskiran, Iftekhar Kalsekar, Rahul Khanna
Introduction: This study evaluated the real-world clinical and economic outcomes associated with the use of the ThermoCool® Surround Flow (SF) and ThermoCool® catheters in atrial fibrillation (AF) ablation. Methods: Adults with AF who underwent catheter ablation between January 1, 2013, and December 31, 2016, in a hospital outpatient setting were identified from the Premier Healthcare Database. Using a search strategy of hospital-charge descriptors, patients were classified into two mutually exclusive groups: ThermoCool® SF catheter and ThermoCool® catheter...
2018: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/30323635/does-knowledge-of-patient-non-compliance-change-prescribing-behavior-in-the-real-world-a-claims-based-analysis-of-patients-with-serious-mental-illness
#6
Jason Shafrin, Katalin Bognar, Katie Everson, Michelle Brauer, Darius N Lakdawalla, Felicia M Forma
Background: New digital technologies offer providers the promise of more accurately tracking patients' medication adherence. It is unclear, however, whether access to such information will affect provider treatment decisions in the real world. Methods: Using prescriber-reported information on patient non-compliance from health insurance claims data between 2008 and 2014, we examined whether prescribers' knowledge of non-compliance was associated with different prescribing patterns for patients with serious mental illness (SMI)...
2018: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/30323634/societal-costs-due-to-meningococcal-disease-a-national-registry-based-study
#7
Nina Gustafsson, Sandra Elkjær Stallknecht, Mette Skovdal, Peter Bo Poulsen, Lars Østergaard
Purpose: Limited detailed evidence exists on the societal costs of meningococcal disease. The objective of this study was to estimate the average 5-year societal cost of events attributable to meningococcal disease in Denmark. Methods: The study was based on the nationwide Danish registries. Incident patients diagnosed with meningococcal disease were identified and each matched with two controls, using direct matching on age, gender, and level of education. Siblings constituted a secondary control population where one patient was matched with one sibling control without meningococcal disease...
2018: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/30288070/impact-of-a-pharmacist-led-diabetes-management-on-outcomes-utilization-and-cost
#8
Daniel D Maeng, Jove Graham, Michael Bogart, Jing Hao, Eric A Wright
Purpose: Pharmacist-led medication therapy disease management (MTDM) has shown improvement in clinical outcomes in patients with certain chronic diseases. However, only limited data demonstrating the impact on health care utilization and cost of care are available. This study seeks to evaluate the impact of a pharmacist-led MTDM program on clinical surrogate outcomes, care utilization, and cost of care among patients with diabetes mellitus. Methods: A retrospective cohort study was conducted by utilizing electronic health records and insurance claims data...
2018: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/30288069/cost-effectiveness-analysis-of-treatment-timing-considering-the-future-entry-of-lower-cost-generics-for-hepatitis-c
#9
Katherine Heath
Background: Cost-benefit analyses are crucial to inform treatment policies, particularly when the cost of patented drugs is very high. The cost of patented drugs is the limiting factor in hepatitis C treatment. However, hepatitis C drug costs are expected to fall following patent expiration, due to generic drug introduction. Methods: An existing mathematical model by Shih et al was extended to consider lower-cost future generics in health economic models of hepatitis C...
2018: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/30271185/cost-of-acute-cough-in-italian-children
#10
Roberto W Dal Negro, Paola Turco, Massimiliano Povero
Objectives: Acute cough is the most common symptom among children in primary care, but the economic impact of cough episodes has never been investigated in Italian families. Materials and methods: A cross-sectional telephone survey was conducted on a representative sample of Italian families, randomly selected from general population. Collected data were analyzed to evaluate the economic impact of cough episodes according to, first, Italian Family Perspective and, second, National Health System Perspective (NHS-P)...
2018: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/30254479/propensity-score-matching-comparison-of-laparoscopic-versus-open-surgery-for-rectal-cancer-in-a-middle-income-country-short-term-outcomes-and-cost-analysis
#11
Daiane Oliveira Tayar, Ulysses Ribeiro, Ivan Cecconello, Tiago M Magalhães, Claudia M Simões, José Otávio C Auler
Background: Laparoscopic surgery for rectal cancer is associated with improved postoperative outcomes compared to open surgery; however, economic studies have yielded contradictory results. The aim of this study was to compare the clinical and economic outcomes of laparoscopic versus open surgery for patients with rectal cancer. Methods: Propensity score matching analysis was performed in a retrospective cohort of patients who underwent elective low anterior resection for rectal cancer treatment by laparoscopic and open surgery in a single Brazilian cancer center...
2018: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/30233223/cost-effectiveness-analysis-of-voriconazole-fluconazole-and-amphotericin-b-for-invasive-fungal-infections-following-allogeneic-hematopoietic-stem-cell-transplantation-in-mexico
#12
Rayo Morfín-Otero, Martha Alvarado-Ibarra, Eduardo Rodriguez-Noriega, Jesus Resendiz-Sanchez, Dipen A Patel, Jennifer M Stephens, Manuela Di Fusco, Carlos F Mendoza, Claudie Charbonneau
Background: Patients receiving allogeneic hematopoietic stem cell transplantation (alloHSCT) are at high risk of invasive fungal infections (IFIs), which are associated with high mortality and economic burden. The cost-effectiveness of prophylaxis for the prevention of IFIs in alloHSCT recipients in Mexico has not yet been assessed. Methods: This analysis modeled a hypothetical cohort of 1,000 patients to estimate costs and outcomes for patients receiving prophylaxis for IFIs following alloHSCT, from the perspective of institutional payers in Mexico...
2018: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/30233222/cost-consequence-analysis-of-fluticasone-furoate-vilanterol-92-22-mcg-for-the-management-of-copd-in-the-spanish-nhs
#13
Laura Amanda Vallejo-Aparicio, Germán Peces-Barba, Alicia Gil, Alicia Huerta Hernandez
Objectives: The Salford Lung Study in Chronic Obstructive Pulmonary Disease (SLS COPD) is a 12-month, open-label randomized clinical trial comparing clinical effectiveness and safety of initiating once-daily fluticasone furoate/vilanterol (FF/VI) 92/22 mcg with continuing usual care (UC) in patients with COPD followed in primary care in the UK. The objective of this analysis is to estimate the economic impact of these results when applied to Spain. Materials and methods: An Excel-based cost-consequence model with a one-year time horizon was populated with SLS COPD results, adopting the Spanish National Health System (NHS) perspective...
2018: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/30214262/incidence-of-febrile-neutropenia-during-chemotherapy-among-patients-with-nonmyeloid-cancer-receiving-filgrastim-vs-a-filgrastim-biosimilar
#14
Lee S Schwartzberg, Lincy S Lal, Sanjeev Balu, Kim Campbell, Lee Brekke, Caitlin Elliott, Stephanie Korrer
Background: Filgrastim and other granulocyte colony-stimulating factors are recommended to decrease febrile neutropenia (FN) incidence among patients with nonmyeloid cancers undergoing chemotherapy. Data comparing biosimilar filgrastim-sndz with reference filgrastim (filgrastim-ref) are limited outside of clinical trials in the US. Objective: To compare the incidence of FN across chemotherapy cycles 1-6 between patients treated with filgrastim-sndz vs filgrastim-ref...
2018: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/30214261/budget-impact-model-of-secukinumab-for-the-treatment-of-moderate-to-severe-psoriasis-psoriatic-arthritis-and-ankylosing-spondylitis-in-italy-a-cross-indication-initiative
#15
Giorgio L Colombo, Sergio Di Matteo, Chiara Martinotti, Steffen M Jugl, Praveen Gunda, Mariantonietta Naclerio, Giacomo M Bruno
Objective: Secukinumab, a fully human monoclonal IgG1 antibody that selectively neutralizes the proinflammatory cytokine IL-17A, has been approved in Europe in 2015 for the treatment of adult patients with moderate-to-severe plaque psoriasis, psoriatic arthritis (PsA), and ankylosing spondylitis (AS). This analysis assessed the budget impact of introduction of secukinumab to the Italian market for all three indications from the perspective of the Italian National Health Service. Materials and methods: A cross-indication budget impact model was developed and included biologic-treated adult patients diagnosed with psoriasis, PsA, and AS...
2018: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/30197528/obesity-in-germany-and-italy-prevalence-comorbidities-and-associations-with-patient-outcomes
#16
Marco DiBonaventura, Antonio Nicolucci, Henrik Meincke, Agathe Le Lay, Janine Fournier
Purpose: This study investigated the association between body mass index (BMI) and three comorbid conditions (type 2 diabetes [T2D], prediabetes, and hypertension) on humanistic and economic outcomes. Patients and methods: This retrospective observational study collected data from German (n=14286) and Italian (n=9433) respondents to the 2013 European Union National Health and Wellness Survey, a cross-sectional, nationally representative online survey of the general adult population...
2018: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/30147350/relapse-prevention-a-cost-effectiveness-analysis-of-brexpiprazole-treatment-in-adult-patients-with-schizophrenia-in-the-usa
#17
Myrlene S Aigbogun, Sizhu Liu, Siddhesh A Kamat, Christophe Sapin, Amy M Duhig, Leslie Citrome
Objective: This study used a decision-analytic framework to assess the cost-effectiveness of brexpiprazole vs comparator branded therapies for reducing relapses and hospitalizations among adults with schizophrenia from a US payer perspective. Methods: An economic model was developed to assess patients with stable schizophrenia initiating treatment with brexpiprazole (1-4 mg), cariprazine (1-6 mg), or lurasidone (40-80 mg) over a 1-year period. After 6 months, patients remained on treatment or discontinued due to relapse, adverse events, or other reasons...
2018: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/30127632/cost-of-opioid-medication-abuse-with-and-without-tampering-in-the-usa
#18
Jeffrey Vietri, Elizabeth T Masters, Alexandra I Barsdorf, Jack Mardekian
Objective: To provide per-patient estimates of the economic burden for opioid medication abuse with and without tampering. Patients and methods: Adults in the US who participated in the 2010 and/or 2011 National Health and Wellness Survey were resurveyed to provide information on use and abuse of prescription opioids in the previous 3 months. Participants (N=20,885) were categorized as those who abused and tampered (n=107), abused without tampering (n=118), those who reported using of opioids as prescribed (n=981), and non-opioid controls (n=19,679)...
2018: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/30100747/the-burden-of-cystic-fibrosis-in-the-medicaid-population
#19
Mariam Hassan, Machaon M Bonafede, Brendan L Limone, Paul Hodgkins, Gregory S Sawicki
Purpose: To conduct an analysis describing clinical characteristics, pulmonary exacerbation (PEx) events, and health care resource utilization among Medicaid-insured patients with cystic fibrosis (CF). Patients and methods: A retrospective analysis of the Truven Health MarketScan® Medicaid Multi-State administrative claims database (2010-2014) was undertaken. Patients aged ≥6 years with a CF diagnosis, continuously enrolled for 12 months, were identified. Demographics, comorbidities, PEx events, and health care resource utilization and costs over a 12-month enrollment period were analyzed for all patients and by age groups...
2018: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/30100746/cost-minimization-analysis-of-degludec-liraglutide-versus-glargine-aspart-economic-implications-of-the-dual-vii-study-outcomes
#20
Enrico Torre, Giacomo Matteo Bruno, Sergio Di Matteo, Chiara Martinotti, Martina Oselin, Maria Chiara Valentino, Alessio Parodi, Luigi Carlo Bottaro, Giorgio Lorenzo Colombo
Background: Diabetes represents a relevant public health problem worldwide due to its increasing prevalence and socioeconomic burden. There is no doubt that tight glycemic control reduces the development of diabetic complications such as the long-term costs related to the disease. The aim of our model was to calculate total direct costs associated with the two treatments considered in DUAL VII study, and hence evaluate the potential economic benefits for the National Health System (NHS) deriving from the use of insulin degludec plus liraglutide (IDegLira) in a once-daily fixed combination...
2018: ClinicoEconomics and Outcomes Research: CEOR
journal
journal
43575
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"